Enhancing antitumor by immunization with fusion of dendritic cells and engineered tumor cells

Abstract

A novel approach for a dentritic cells (DCs)-based tumor vaccine was developed for the formation of hybrid-engineered J558 after fusion with DCs. To make the hybrid-tumor vaccine generate more efficient specific CTL cytotoxicity against wild-type tumor cells, we genetically engineered tumor cells with mIL-12 gene prior to the cell fusion. mIL-12 was detected at 870±60 pg/(10⁵ cells/ml) in the culture supernatants and the fusion ratio was about 30% by the co-focal microscopic analysis. Vaccination of mice with DCs fused with engineered J558 induced more efficient tumor-specific CTL cytotoxicity against wild-type tumor cellsin vitro and with efficient antitumor immunityin vivo. These results suggest that this approach of using DCs fused with engineered tumor cells could be applied in clinical settings of DCs-based cancer vaccines.

Keywords

dendritic cell / tumor vaccine / engineered tumor cells / IL-12 / antitumor immunity

References

[1] KimT S, ChungS W, HwangS Y. Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7. 1 and interleukin-7. Vaccine, 2000, 18: 2886-2886

[2] XiangJ, ChenY, MoyanaT. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Ther, 2000, 7: 1023-1023

[3] NelsonW G, SimonsJ W, MikhakB, et al. . Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol, 2000, 46: 67-67

[4] CellaM, SallustoF, LanzavecchiaA. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol, 1997, 9: 10-10

[5] SongW, KongH, CarpenterH, et al. . Dendritic cells genetically modified with adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med, 1997, 186: 1247-1247

[6] AokiT, TashiroK, MiyatakeS, et al. . Expression of murine interleukin 7 in a murine glioma cell lines results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA, 1992, 89: 3850-3850

[7] WakimotoH, AbeJ, TsunodaR, et al. . Intensified anti-tumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res, 1996, 56: 1828-1828

[8] HartI, ColacoC. Immunotherapy: Fusion induces tumour rejection. Nature, 1997, 338: 626-626

[9] GhattasI R, SanesJ R, MajorsJ E. The encephalomy-ocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol, 1991, 11: 5848-5848

[10] ZitvogelL, TaharaH, CaiQ, et al. . Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther, 1994, 5: 1493-1493

[11] SgadariC, AngiolilloA L, TosatoG. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 1996, 87: 3877-3877

[12] MeleroI, MazzoliniG, NarvaizaI, et al. . IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol, 2001, 22: 113-113

[13] CaoX, ZhangW, WangJ, et al. . Therapy of established tumor with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology, 1999, 97: 616-616